Finch Therapeutics
Somerville, US · Founded 2017 · Delaware corporation · 13 employees on LinkedIn · 6 known investors
Find your way into Finch Therapeutics
763 people in our graph share verified history with the Finch Therapeutics team — schools, employers, funds. One of them is your warm intro.
Tsendai Chagwederaunlockedknows Mark Smith · together at Massachusetts Institute of Technology (overlapped)
×5knows the team · via Princeton University
×3knows the team · via Massachusetts Institute of Technology
×3knows the team · via Case Western Reserve University
Finch Therapeutics is a life sciences company focused on the development and protection of drug-related intellectual property and therapeutics within the biotechnology and pharmaceutical industry.
Founders & leadership
Finch Therapeutics was founded in 2017 by Mark Smith.
MS
Mark SmithinFounder · CEO2016–2023Mark Smith completed a PhD at MIT studying computational methods for microbial networks. He founded OpenBiome to advance clinical microbiome therapies before establishing Finch Therapeutics (NASDAQ: FNCH) to develop microbial-based drug candidates, including work with Takeda Pharmaceuticals on inflammatory bowel disease treatments.
MB
Matt BlischakinChief Executive OfficerMatt Blischak is CEO of Finch Therapeutics, a biotechnology company developing therapeutics and managing related intellectual property. He has held strategic advisory roles focused on global intellectual property management, including patent strategy, litigation, licensing, and enforcement across US and foreign jurisdictions.
RJ
R. J. PriceNamed on SEC filing
JA
Jeffery A. SmisekNamed on SEC filing
AM
Andrew MulderryNamed on SEC filing
JB
James BurgessNamed on SEC filing
AN
Andrew NohNamed on SEC filing
ZK
Zain KassamNamed on SEC filing
BE
Benjamin EnersonNamed on SEC filing
Board
CL
Investors · 6
Reported raises · per SEC filings
Form D private placements$179.9M disclosed across 3 rounds · 2018–2020
▶$90MraisedSep 2020 · 43 investors · BiotechnologyRule 506(b)
▶$90MraisedSep 2020 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Domenic FerranteDirector
- Jo VineyDirector
- Zain KassamExecutive Officer
- Jeffery A. SmisekDirector
- Mark SmithExecutive Officer, Director
- Christopher CosmidesDirector
- Benjamin EnersonExecutive Officer
- James BurgessExecutive Officer
- Andrew MulderryDirector
- Andrew NohExecutive Officer
- Chris LangeDirector
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$53.5MraisedJul 2019 · 22 investors · BiotechnologyRule 506(b)
▶$53.5MraisedJul 2019 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MulderryDirector
- Chris LangeDirector
- Domenic FerranteDirector
- Jeffery A. SmisekDirector
- Alan GrossDirector
- Greg PerryExecutive Officer
- Ulrich ThienelExecutive Officer
- Mark SmithExecutive Officer, Director
- Andrew NohExecutive Officer
- Benjamin EnersonExecutive Officer
- Zain KassamExecutive Officer
- James BurgessExecutive Officer
- Offering amount
- $53.5M
- Amount sold
- $53.5M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$36.4MraisedMar 2018 · 14 investors · BiotechnologyRule 506(c)
▶$36.4MraisedMar 2018 · 14 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- R. J. PriceDirector
- Jeffery A. SmisekDirector
- Mark SmithExecutive Officer, Director
- Andrew MulderryDirector
- Chris LangeDirector
- James BurgessDirector
- Andrew NohDirector
- Zain KassamExecutive Officer
- Benjamin EnersonExecutive Officer
- Offering amount
- $36.4M
- Amount sold
- $36.4M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Finch18 shared keywordsFinch provides an API platform for applications to securely access employer and employee data with explicit consent, serving businesses that need workforce data integration. The company prioritizes enterprise-grade security, encryption, and compliance standards.
Finch9 shared keywordsFinch provides outsourced legal operations for personal injury plaintiff firms, combining US-based intake specialists, case managers, paralegals, and demand writers with proprietary AI to handle intake, investigation, records, bills, liens, and demands. It aims to help firms process more cases faster while keeping their existing case management and document systems updated.
Companies competing with Finch Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Finch Therapeutics do?
- Finch Therapeutics is a life sciences company focused on the development and protection of drug-related intellectual property and therapeutics within the biotechnology and pharmaceutical industry.
- Who founded Finch Therapeutics?
- Finch Therapeutics was founded by Mark Smith in 2017.
- Who are Finch Therapeutics's investors?
- Finch Therapeutics's investors include B3 Holding, Octave Ventures Llc, OCV Partners, OMX Ventures, Shumway Capital, Humboldt.
- How much funding has Finch Therapeutics raised?
- Finch Therapeutics has disclosed $179.9M raised across 3 rounds.
- Where is Finch Therapeutics headquartered?
- Finch Therapeutics is headquartered in Somerville, US.